Positive Results from Mid-term Trial of ABCL635 for Hyperhidrosis Treatment, AbCellera Biologics (ABCL.US) Soars.

Canadian biotechnology company AbCellera Biologics (ABCL.US) saw its stock price increase nearly 35% on Monday, with intraday gains exceeding 44%. The company announced that a potential drug for treating hot flashes achieved its primary endpoint in a mid-stage clinical trial, demonstrating efficacy. It is reported that ABCL635 is a potential first-in-class antibody drug developed by AbCellera Biologics, designed to provide a non-hormonal treatment option for vasomotor symptoms (VMS), commonly known as hot flashes, related to menopause. The drug aims to block a biological signal associated with hot flashes, which can cause sudden and uncomfortable sensations of heat in the body and affect sleep quality. AbCellera Biologics released the results of a clinical trial assessing the drug's efficacy in 92 postmenopausal female patients, who received either the drug or a placebo. The company stated that during the four-week study, patients receiving the experimental injection treatment experienced a reduction in both the frequency and severity of hot flashes compared to those receiving placebo, with no serious side effects reported. Additionally, ABCL635 was observed to significantly improve sleep quality and the patients' overall condition improvement score (PGI-C). The most common adverse reactions reported by patients receiving the drug included headache, fatigue, and injection site reactions. AbCellera CEO Carl Hansen stated on Monday, "We believe ABCL635 has the potential to be a blockbuster product. Its efficacy data even exceeds our previously most optimistic scenarios." He added that because the drug is a non-hormonal treatment, it has significant market potential. Currently available hormone therapies are unsuitable for approximately 20% of female patients. However, the drug still needs to undergo further clinical trials.